Stock Splits Matter: Here’s What’s Coming Up Soon
Here is a look at why companies split their stocks and why it matters. Plus, upcoming stock splits to watch from a Coca-Cola bottler, Southern Copper, and more.
Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: MCRB serestherapeutics.com
Seres Therapeutics is a clinical-stage biotechnology company developing oral live biotherapeutics. These are consortia of bacteria manufactured from master cell banks and designed to target the gastrointestinal mucosal epithelial barrier-immune interface. Its programs are in oncology and inflammatory and immune diseases.
The company previously developed VOWST, the first FDA-approved orally administered microbiome therapeutic, and sold the VOWST business to Nestlé Health Science. It received a final [USD:12500000] milestone buy-out payment in October 2026. Current revenue consists solely of grant revenue, including CARB-X support.
Its pipeline includes:
- SER-155 (Breakthrough Therapy and Fast Track designations) for preventing bloodstream infections in allogeneic stem cell transplant patients; Phase 2 ready pending funding.
- SER-155 for preventing immune checkpoint inhibitor-related enterocolitis (irEC); an FDA study design submission is planned for Q1 2027.
- SER-428, a liquid formulation for ICU patients at risk of antimicrobial-resistant infections.
- SER-603 for inflammatory bowel disease, in IND-enabling studies.
- SER-147 for spontaneous bacterial peritonitis in cirrhosis, at the preclinical stage.
The company relies on its AI-enabled MbTx platform for discovery. It is seeking partnerships and capital, with cash runway projected only into Q1 2027. Updated
Here is a look at why companies split their stocks and why it matters. Plus, upcoming stock splits to watch from a Coca-Cola bottler, Southern Copper, and more.
2015 was one of the worst years for IPOs in the past decade. Only 2016 and 2022 were worse. But there were some big winners.
One of Cathie Wood's ARK Invest exchange-traded funds sold over 840,000 shares of Seres Therapeutics on August 30.
Friday's top analyst upgrades and downgrades included American Airlines, Boston Beer, CarMax, Danaher, Domino’s Pizza, D.R. Horton, Monster Beverage and Starbucks.
Tuesday's top analyst upgrades and downgrades included Bed Bath & Beyond, Booking, Carvana, Electronic Arts, EOG Resources, Honeywell, Intercontinental Exchange, Livongo Health, Nucor, Seres Therapeutics and Sunrun.
Seres Therapeutics is a clinical-stage biotechnology company developing oral live biotherapeutics. These are consortia of bacteria manufactured from master cell banks and designed to target the gastrointestinal mucosal epithelial barrier-immune interface.
The Wall Street consensus 12-month price target for MCRB is $17.00.